Interpace Diagnostics Group, Inc.-Interpace Biosciences Announces First Quarter 2025 Financial and Business Results

●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of$ 11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately$ 38 million PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results fo ...